ADMS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States...

Stats
Dzisiejszy wolumen	3.15M
Średni wolumen	1.34M
Kapitalizacja rynkowa	0.00
EPS	$-0.430 ( 2021-11-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.189 (2.30%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-24	Mahoney David L	Sell	112 781	Common Stock
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	40 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)
2021-11-24	Mahoney David L	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 2 100 832 \| Sell: 2 425 856

Wolumen Korelacja

Długi: 0.29 (neutral)

Krótki: 0.76 (moderate)

Signal:(73.528) Neutral

Adamas Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje
BSQR	0.989
SLNO	0.983
BRACU	0.965
XLRN	0.964
LABP	0.962
HCTI	0.961
CEG	0.959
EBAY	0.957
CYT	0.956
CRAI	0.953

10 Najbardziej negatywne korelacje
AGZD	-0.992
TWKS	-0.967
UNAM	-0.962
HRZN	-0.958
MORF	-0.958
SMSI	-0.954
LPSN	-0.945
BAFN	-0.945
PEBK	-0.941
AHPI	-0.94

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Adamas Pharmaceuticals Korelacja - Waluta/Towar

0.70
( moderate )

-0.08
( neutral )

0.42
( neutral )

0.54
( weak )

-0.70
( moderate negative )

Adamas Pharmaceuticals Finanse

Annual	2020
Przychody:	$74.46M
Zysk brutto:	$72.42M (97.26 %)
EPS:	$-1.632

FY	2020
Przychody:	$74.46M
Zysk brutto:	$72.42M (97.26 %)
EPS:	$-1.632

FY	2019
Przychody:	$54.64M
Zysk brutto:	$52.17M (95.48 %)
EPS:	$-3.80

FY	2018
Przychody:	$34.05M
Zysk brutto:	$33.41M (98.14 %)
EPS:	$-4.87

Financial Reports:

No articles found.

Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.